Make an appointment with a cancer specialist today.
Call us at 800-KARMANOS (800-527-6266)

News

Karmanos breast cancer research team highlighted on cover of journal of cancer biology, therapy

Scientists at the Barbara Ann Karmanos Cancer Institute have their research highlighted on the cover of this month’s “Cancer Biology & Therapy.”

The title of the research piece is, “Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.”

Authors include Pratima Nangia-Makker, Ph.D., of the departments of Oncology and Pathology at Karmanos and Wayne State University School of Medicine (WSU SOM); Tirza Raz, member of the Department of Oncology at WSU SOM; Larry Tait, research associate with Karmanos and WSU SOM, Malathy Shekhar, Ph.D., associate professor of Oncology at WSU SOM and the Molecular Therapeutics Program of Karmanos Cancer Institute; Hong Li, Ph.D., of the Department of Biological and Chemical Engineering, Chongqing University of Education, Chongqing, China; Vitaly Balan, Ph.D., assistant professor in the Department of Oncology at Karmanos and WSU SOM; Hemanckur Makker, a member of the Department of Chemistry at WSU SOM:  Rafael Fridman, Ph.D., associate professor in the Cancer Biology Program at Karmanos and WSU SOM; Krishnarao Maddipati, Ph.D., assistant professor in the Department of Pathology at WSU SOM; and Avraham Raz, Ph.D., of the Department of Oncology at Karmanos and WSU SOM.

Researchers examined the role of Ocimum gratissimum, also known as the herb holy basil or tulsi, and the derivative compounds of this herb, in inhibiting the migration of breast cancer cells, and the growth and progression of ductal carcinoma in situ.

To read more about their research, click http://www.landesbioscience.com/journals/cbt/article/23762/#

We congratulate this research group on their accomplishments!

© 2014 Karmanos Cancer Institute Pencil
The Barbara Ann Karmanos Cancer Center is accredited by The Joint Commission.
If members of the public have any quality-of-care or safety concerns, they may notify The Joint Commission at 630-792-5800.